Makito Kanako, Matsuo Yuichiro, Matsui Hiroki, Fushimi Kiyohide, Yasunaga Hideo
Department of Biostatistics, School of Public Health, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
J Anesth. 2025 Jul 16. doi: 10.1007/s00540-025-03548-0.
Desflurane and sevoflurane are widely used for general anesthesia; however, it remains uncertain if sevoflurane might be preferable for patients with chronic respiratory inflammatory diseases. This study compared postoperative outcomes of desflurane and sevoflurane following gastrointestinal cancer surgery in patients with chronic obstructive pulmonary disease (COPD) or asthma.
We conducted a retrospective cohort study using the Japanese Diagnosis Procedure Combination database (April 2011-March 2022), identifying patients with COPD or asthma who underwent gastrointestinal cancer surgery. The primary outcome was postoperative pulmonary complications, including pneumonia, respiratory failure, mechanical ventilation > 24 h, and unplanned reintubation within 7 days after surgery. Secondary outcomes were in-hospital mortality and postoperative stay. We conducted propensity score overlap weighting and instrumental variable analyses adjusted for confounders.
We identified 24,243 COPD and 16,199 asthma patients. Propensity score overlap weighting showed no significant association between desflurane and increased postoperative pulmonary complications in COPD [adjusted risk difference (aRD) - 0.57%; 99% confidence interval (CI), - 1.8% to 0.60%] or asthma (aRD, - 0.62%; 99% CI, - 1.8% to 0.59%). In-hospital mortality did not differ significantly between groups in COPD (aRD, - 0.24%; 99% CI, - 0.76% to 0.29%) or asthma (aRD, 0.07%; 99% CI, - 0.45% to 0.59%). The postoperative stay also showed no significant association between the desflurane and sevoflurane groups.
Desflurane-based anesthesia was not associated with increased postoperative pulmonary complications and mortality compared to sevoflurane in patients with chronic respiratory diseases undergoing gastrointestinal cancer surgery. However, further studies using reliable diagnostic criteria to assess COPD or asthma are warranted.
地氟烷和七氟烷广泛用于全身麻醉;然而,七氟烷对于患有慢性呼吸道炎症性疾病的患者是否更具优势仍不确定。本研究比较了慢性阻塞性肺疾病(COPD)或哮喘患者在胃肠道癌手术后使用地氟烷和七氟烷的术后结局。
我们使用日本诊断程序组合数据库(2011年4月至2022年3月)进行了一项回顾性队列研究,确定了接受胃肠道癌手术的COPD或哮喘患者。主要结局是术后肺部并发症,包括肺炎、呼吸衰竭、机械通气>24小时以及术后7天内的非计划再次插管。次要结局是住院死亡率和术后住院时间。我们进行了倾向评分重叠加权和调整混杂因素的工具变量分析。
我们确定了24243例COPD患者和16199例哮喘患者。倾向评分重叠加权显示,在COPD患者中,地氟烷与术后肺部并发症增加之间无显著关联[调整风险差异(aRD)-0.57%;99%置信区间(CI),-1.8%至0.60%],在哮喘患者中也无显著关联(aRD,-0.62%;99%CI,-1.8%至0.59%)。COPD患者组间住院死亡率无显著差异(aRD,-0.24%;99%CI,-0.76%至0.29%),哮喘患者组间也无显著差异(aRD,0.07%;99%CI,-0.45%至0.59%)。术后住院时间在地氟烷组和七氟烷组之间也无显著关联。
在接受胃肠道癌手术的慢性呼吸道疾病患者中,与七氟烷相比,基于地氟烷的麻醉与术后肺部并发症和死亡率增加无关。然而,有必要使用可靠的诊断标准进行进一步研究以评估COPD或哮喘。